ART And The National Research Council of Canada Institute for biological sciences to jointly develop commercial applications for O

NRC Institute for Biological Sciences is collaborating with ART to develop state-of-the-art molecular imaging solutions for preclinical and clinical research. NRC-IBS and ART have agreed to establish a partnership consisting of service, research and development activities. In collaboration with NRC-IBS, new diagnostic applications of ART’s time domain technology and equipment for use in disease models will be developed and adopted by ART for application notes.

“The NRC-IBS is very pleased to collaborate with ART for the development of better diagnostics using molecular imaging, which can help identify and characterize brain-specific targets, and develop improved therapies for neurodegenerative diseases affecting the aging population. Optical imaging-based approaches also promise to accelerate drug evaluation and shorten the time to their clinical application”, said Dr. Abedelnasser Abulrob, Research Officer at the NRC-IBS. Dr. Abulrob recently participated in a webcast to the scientific research community, launching ART’s new in vivo optical imager, Optix® MX2. During this webcast, Dr. Abulrob provided experimental examples from his own research on the capabilities of Optix’s analytical software package, OptiView™. Dr. Abulrob’s team has been using the Optix system for new applications of optical imaging and fluorescence lifetime, in addition to the evaluation of investigative drugs in stroke and Alzheimer's disease and brain cancer.

“The scientific exchange and collaboration between the NRC-IBS and ART has already proven beneficial for advancing both scientific discovery and technology development in the emerging field of molecular imaging. This collaboration agreement with the NRC-IBS creates new opportunities to respond to the challenges faced by our customers in drug development. Now, by contributing to enable novel Optix applications, the NRC will play an important role in advancing our plan to develop solutions for our clients and help them shorten the drug development cycle,” said Mr. Sébastien Gignac, ART’s President and CEO.

(Source: ART)